ReviewFrontiers in cell and developmental biology2026
Regulatory mechanisms of programmed cell death in hyperuricaemia and their disease relevance.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricaemia (HUA) is a metabolic disorder that can not only predispose patients to gout but also be associated with renal, cardiovascular, and metabolic diseases. Recent evidence has designated programmed cell death (PCD) as a central event that drives tissue injury and inflammation in HUA. Raised soluble urate and exposure to monosodium urate (MSU) crystals activate separate but shared stress and injury pathways, including apoptosis, pyroptosis, ferroptosis, and necroptosis in concert with dysregulated autophagy. These processes converge through oxidative stress, mitochondrial dysfunction and signalling along the inflammasome-immune axis to influence disease progression. Among these cell death modalities, the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated pyroptosis is a crucial amplifier of urate-induced inflammation and concomitant cellular injury; ferroptosis also contributes to irreversible organ damage along with impaired autophagy. More importantly, extensive crosstalk among these pathways collectively shapes disease trajectory and outcomes. This Review summarises the main regulatory mechanisms that promote PCD during HUA, with a focus on renal injury, cardiovascular damage and metabolic dysregulation. Distinct from pathway-specific summaries, this Review integrates apoptosis, pyroptosis, ferroptosis and necroptosis together with autophagy-related dysfunction into a unified disease-relevance framework linking urate-associated stress, pathway crosstalk and organ-specific injury in HUA. Current limitations and novel therapeutic targets are also discussed to inform basic mechanistic studies together with potential clinical strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.